Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections

Valeria Manfreda; Maria Esposito; Elena Campione; Luca Bianchi; Alessandro Giunta

doi:10.1080/00325481.2019.1575613

Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections

Postgrad Med. 2019 Apr;131(3):239-240. doi: 10.1080/00325481.2019.1575613. Epub 2019 Feb 8.

Authors

Valeria Manfreda¹, Maria Esposito¹, Elena Campione¹, Luca Bianchi¹, Alessandro Giunta^{1

2}

Affiliations

¹ a Department of Dermatology , University of Rome "Tor Vergata" , Rome , Italy.
² b Dermatology, Department of Clinical Sciences and Translational Medicine, International Medical School , University of Rome "Tor Vergata" , Rome , Italy.

PMID: 30700196
DOI: 10.1080/00325481.2019.1575613

Abstract

Treatment of psoriasis and psoriatic arthritis in patients with concomitant chronic, severe viral infections, particularly HIV or HBV, represents a challenge, due to contraindication to conventional immunomodulating systemic drugs and biologics, including anti-TNF alpha, anti-IL12/23, and anti-IL17 agents. Recently, apremilast, a selective inhibitor of phosphodiesterase E4 has been suggested to be a safe and effective therapeutic option in HIV-infected population with psoriatic arthritis. We report the case of a patient with psoriatic arthritis and concomitant HIV and HBV infection successfully treated with apremilast.

Keywords: Apremilast; HIV; psoriasis; psoriatic arthritis.

Publication types

Case Reports

MeSH terms

Adolescent
Anti-Inflammatory Agents, Non-Steroidal / adverse effects
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
Arthritis, Psoriatic / complications
Arthritis, Psoriatic / drug therapy*
HIV Infections / complications*
Hepatitis B / complications*
Humans
Male
Thalidomide / adverse effects
Thalidomide / analogs & derivatives*
Thalidomide / therapeutic use
Treatment Outcome

Substances

Anti-Inflammatory Agents, Non-Steroidal
Thalidomide
apremilast